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78Influence of Nucleated Cell Dose on Overall Survival
of Unrelated Cord Blood Transplantation for Patients
with Severe Acquired Aplastic Anemia: A Study
by Eurocord and the Aplastic Anemia Working
Party of the European Group for Blood
and Marrow Transplantation
Regis Peffault de Latour,1 Duncan Purtill,2 Annalisa Ruggeri,2 Guillermo Sanz,3
Gerard Michel,4 Virginie Gandemer,5 Sebastien Maury,6 Joanne Kurtzberg,7
Carmen Bonfim,8 Mahmoud Aljurf,9 Eliane Gluckman,2 Gerard Socie,1
Jakob Passweg,10 Vanderson Rocha1,2Information is scarce on outcomes after unrelated cord blood transplantation (UCBT) for patients with se-
vere aplastic anemia (SAA). We retrospectively analyzed 71 patients (median age, 13 years; 28 adults) with
SAA (9 with paroxysmal nocturnal hemoglobinuria [PNH]) who received a single-unit (n 5 57; 79%) or
double-unit UCBT (n 5 14; 19%) in 32 centers between 1996 and 2009. A reduced-intensity conditioning
regimen was provided in 68% of the patients. The cumulative incidence (CI) of neutrophil recovery was
51%6 6% at day 60, with significantly better engraftment seen in recipients of higher prefreezing total nucle-
ated cell (TNC) dose (.3.9 107/kg; hazard ratio [HR], 1.5; P5.05). The CI of platelet engraftment at day 180
posttransplantation was 37%6 7%, that of grade II-IVacuteGVHDwas 20%6 5%, and that of chronic GVHD
at 3 years was 18%6 5%. At amedian follow-up of 35months (range, 3-83months), the estimated probability
of 3-year overall survival (OS) was 38% 6 6%. Significantly improved OS was seen in recipients of .3.9 107
TNCs/kg prefreezing (45%, compared with 18% for recipients of #3.9 107 TNC/kg; HR, 0.4; P 5 .007).
These results highlight the fundamental role of cell dose for both engraftment and OS in patients with SAA
undergoing UCBT.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) from an HLA-matched related donor is the
treatment of choice for patients with severe aplastic
anemia (SAA) [1]. In the absence of an HLA-identical
sibling, the current standard treatment for SAA is the
combination of antithymocyte globulin (ATG) and
cyclosporine (CsA) [2]. After immunosuppressive
therapy (IST), overall response is achieved in about
two-thirds of patients, the cumulative incidence (CI)
of relapse among responders is approximately 20%-
30%, and clonal evolution occurs in about 10%-15%
of cases [3-5]. Both refractory and relapsed patients
are treated with repeated courses of IST. Patients
refractory to initial IST historically have a dire
outcome, with long-term survival rates of 20%-30%
[4], whereas the response rate is about 40%-50% in
relapsed patients [6]. The management of patients
Biol Blood Marrow Transplant 17:78-85, 2011 79Cord Blood Transplantation and Aplastic Anemiawith refractory or recurrent SAA is challenging.HSCT
fromanunrelated donor (UD) represents an alternative
salvage therapy for those patients.
The outcome of HSCT with UD transplants for
patients with SAA has improved in the last decade
[7,8]. Better donor-recipientHLAmatching has played
a major role in this improvement, but significant
changes in the conditioning regimen and supportive
measures have contributed as well [9,10]. The recent
study on UD-HSCT from the SAA Working Party of
the European Group for Blood and Marrow Trans-
plantation (SAA WP-EBMT), included a total of 100
patients with SAA. The 5-year overall survival (OS)
rate was 75%, with low incidences of both acute and
chronic graft-versus-host disease (aGVHD, cGVHD)
[11]. Results of UD-HSCT have improved to such an
extent as to possibly affect treatment strategies. In chil-
dren without a matched sibling donor, current guide-
lines recommend proceeding to HSCT after a failure
of one course of IST, provided that a fully matched do-
nor at the allele level formajor histocompatability com-
plex class I and II antigen is available [12]. In adults, an
alternative donor transplant is an option for second-
line treatment in patients failing one or two courses
of IST [8,13].
Unfortunately, many patients, especially those
from ethnic minority groups or less-homogeneous
populations, do not have a suitable UD. The percent-
age of such patients will vary between 5% and 40%, ac-
cording to the patient’s ethnic origin [13]. Unrelated
cord blood transplantation (UCBT) is an alternative
option that has been successfully used in patients with
hematologic malignancies [14,15]. To date, there
have been only a few reports on UCBT in patients
with SAA. Primary reports showed poor outcomes
and a high incidence of graft failure [14,16], whereas
some later small series and case reports have reported
successful UCBT for SAA [17-20]. The largest
cohort reported to date, 31 patients in a Japanese
study, had a 2-year OS of 41%, suggesting that
UCBT can be an alternative treatment for SAA
patients who fail IST and have no suitable donor [21].
We conducted a retrospective analysis on 71 patients
diagnosed with SAA (9 with paroxysmal nocturnal
hemoglobinuria [PNH]) who underwent UCBT in
32 centers (including 23 EBMT centers).PATIENTS AND METHODS
Data Collection
Eurocord is a registry of related and UCBT that
works in collaboration with the EBMT and Netcord
banks. Eurocord and EBMT databases provided data
on UCBT. Centers not associated with EBMT were
asked to complete reports if UCB units were obtained
fromNetcord banks. All data were verified and updatedby the institution’s physicians and data managers. All
patients or legal guardians provided informed consent
for theUCBTaccording to theDeclarationofHelsinki.
Inclusion Criteria
This retrospective study included patients with
SAA (based on the criteria of the International Agran-
ulocytosis and Aplastic Anemia Study) (1) who received
an unrelated and unmanipulated single-unit or double-
unit UCBT; (2) who were older than 1 year at the time
of diagnosis of SAA; and (3) for whom there were
adequate and sufficient data to perform the analysis.
Patients with PNH were included in case of SAA and
a sublinical PNH clone. In the Eurocord database,
there was no patient with classic PNH (including he-
molysis and thrombosis). Patients with constitutional
bone marrow (BM) failure were excluded from the
study because most of them have been previously re-
ported [22] as well as patients who had received a previ-
ous allograft. In June 2009, 71 out of 439 patients
transplanted for BM failure syndrome (BMFS) and reg-
istered on the Eurocord registry were eligible for this
study.
Endpoint Definitions
The primary endpoint was OS at 3 years. Other
endpoints included incidence of neutrophil recovery,
defined as the first of 3 consecutive days with a neutro-
phil count of at least 0.5  109/L, and the incidence of
platelet recovery as the first of 7 consecutive days with
an unsupported platelet count of at least 20  109/L.
Graft failure was defined as no sign of neutrophil recov-
ery, as well as transient engraftment of donor cells up to
60 days posttransplantation. Reduced-intensity condi-
tioning (RIC) was defined according to published crite-
ria [23]. aGVHD and cGVHD were diagnosed and
graded according to published criteria [24], with histo-
pathologic confirmation when possible. Chimerism
datawas evaluated in thefirst 3months posttransplanta-
tion. Full donor chimerism was defined as the presence
of.95% of the cells of donor origin, mixed chimerism
if .5% and\95% of donor cells, and autologous re-
covery if\5% of donor cells. Data on the method of
chimerism detection were not reported.
Statistical Analysis
Data were analyzed through June 2009. The CI
function (CIF), using death as a competing event, was
used to estimate neutrophil and platelet engraftment
and aGVHDand cGVHD.TheKaplan-Meiermethod
was used to estimate OS. The variables evaluated in-
cluded recipient age, donor sex, recipient-donor sex
mismatch, number of pre-UCBT transfusions for red
blood cells (RBCs) and platelets, recipient cytomegalo-
virus (CMV) serologic status, disease duration before
UCBT, single-unit versus double-unit transplant,
Table 1. Patient and Disease Characteristics (n 5 71)
Characteristic n/N (%) or Median (Range)
Age at transplantation, years 13 (2-68)
Children (age <18 years) 43 (61%)
Weight at transplantation, kg* 47 (9-100)
Males/females 38/33
Recipient CMV-positive 43/68 (63%)
Diseases
SAA† 62/71 (87%)
PNH 9/71 (13%)
Previous immunosuppressive treatment 55/62 (89%)
Time interval from diagnosis of SAA to
transplantation, months
14 (2-140)
More than 20 red blood cell units infused 35/63 (56%)
More than 20 platelet transfusions 42/63 (56%)
CMV indicates cytomegalovirus; SAA, severe aplastic anemia; PNH,
paroxysmal nocturnal hemoglobinuria.
*Twenty-nine 29 patients weighed >50 kg.
†Including 1 patient with posthepatitis SAA.
Table 2. Graft- and Transplantation-Related Characteristics
Characteristic n/N (%) or Median (Range)
Number of unrelated CB units
1 57 (79%)
2 14 (19%)
Number of HLA disparities*
6/6 match 5 (10%)
5/6 match 17 (33%)
4/6 match 26 (51%)
3/6 match 3 (6%)
Number of HLA disparities†
2 units 5/6 match 2 (14%)
2 units 4/6 match 6 (43%)
2 units 3/6 match 1 (7%)
1 unit 5/6 and 1 unit 4/6match 2 (14%)
Number of nucleated cells collected,  107/kg
Single CB 4.3 (2-35)
Double-unit CB 7.4 (5-15)
Number of CD34+ cells collected,  105/kg
Single CB 2.1 (0.4-19)
Double-unit CB 3 (1-87)
Number of nucleated cells infused,  107/kg
Single CB 3.2 (1.5-16)
Double-unit CB 6.2 (3.2-13.2)
Number of CD34+ cells infused,  105/kg
Single CB 1.8 (0.3-7.8)
Double-unit CB 2.9 (1.1-7.1)
Conditioning regimen‡
RIC 48 (68%)
Flu-based regimen 31 (46%)
Myeloablative 22 (31%)
Cy + Bu 10 (15%)
Cy + TBI 12-14 Gy 8 (12%)
Use of TBI
Low-dose 14 (21%)
High-dose 11 (16%)
GVHD prophylaxis§
CsA + prednisone 38 (55%)
CsA + mycophenolate mofetil 13 (19%)
Other 18 (26%)
Use of ATG 53/67 (79%)
CB indicates cord blood; RIC, reduced-intensity conditioning; Flu,
fludarabine; Cy, cyclophosphamide; Bu, busulfan; TBI, total body irradi-
ation; CsA, cyclosporine A; ATG, antithymocyte globulin.
*One unit, antigen-level HLA-A and -B and allele-levelHLA-RDB1 typing.
†Two units, antigen-level HLA-A and -B and allele-level HLA-RDB1
typing; 3 missing data on the second unit.
‡Four missing data on conditioning regimen.
§Two missing data on GVHD prophylaxis.
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high-resolution DNA typing, number of mononuclear
cells and CD341 cells of the cord blood units at the
time of freezing and infusion, conditioning regimen,
and year of UCBT. Continuous variables were catego-
rized as follows. Each variable was first divided into 3
categories of percentiles; if the relative event rates (ratio
of the observed number of events to the expected num-
ber of events in a category, assuming no variation across
categories) in 2 or more adjacent categories (and the
mean times to event) were not substantially different,
these categories were then grouped. The best cutoff
point of total nucleated cell (TNC) dose was the 33rd
percentile for survival and neutrophil recovery; for the
other variables, no clear pattern was observed for the
primary outcome, and thus the median was taken as
a cutoff point [25]. For assessment of prognostic factors
using theCIF, univariate andmultivariate analyseswere
performed using Gray’s test [26] and the proportional
subdistribution hazard regression model of Fine and
Gray [27]. For OS, the log-rank test and the Cox pro-
portional hazards model were used in univariate and
multivariate analyses. Each potential risk factor was
tested independently. All factors that reached P #.10
in the univariate analysis were included in themultivar-
iate model. All models were built using a forward
stepwise method. Only factors that reached P #.05
were retained in the final model. Statistical analyses
were performed with SPSS (SPSS Inc, Chicago, IL),
and S-PLUS (Insightful Corp, Seattle, WA) software
packages.RESULTS
Patient and Disease Characteristics
A total of 71 patients from 23 EBMT transplant
centers and 9 non-EBMT centers who underwent
UCBT between January 1996 and June 2009 met the
criteria for inclusion into the study. Patient and diseasecharacteristics are summarized in Table 1. As shown,
most patients had failed a first course of IST (n 5 55;
89%) and were heavily transfused before transplanta-
tion; 35 patients received .20 RBC units (56%), and
42 patients received .20 platelet transfusions (67%).
The median time from diagnosis of SAA to transplan-
tation was 14 months (range, 2-140 months).Graft and Transplant Characteristics
Graft and transplant-related characteristics are sum-
marized in Table 2. A total of 57 patients received a sin-
gle-unit UCBT, and 14 received a double-unit UCBT.
Theconditioning regimenvariedaccording to the trans-
plant center. A total of 48 patients received an RIC
regimen, and 22 received a myeloablative (MA) condi-
tioning regimen; information on condition reducing
Table 3. Univariate Analysis for Outcomes after UD UCBT
in Patients with SAA (n 5 71)
Neutrophil Engraftment
at Day 60
OS at
3 Years
Covariate n (% ± SD) n (% ± SD)
Age, years
>13 36 53 ± 8.5 36 45 ± 9
#13 35 46 ± 8.5 35 32 ± 8
P .72 .44
Recipient sex
Male 33 39 ± 8.5 33 14 ± 7
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monly used RIC regimens were cyclophosphamide
(Cy; 50-200 mg/kg) 1 fludarabine (Flu; 90-200mg/
m2) 1 ATG (n 5 15), Cy (50-200 mg/kg) 1 ATG
(n 5 10), and Cy (50-100 mg/kg) 1 Flu (120-200 mg/
m2)1TBI (2Gy)1ATG (n5 7). Themost commonly
usedMA regimens were Cy (90-200 mg/kg)1 busulfan
(Bu; 4.8-20mg/kg) 1 ATG (n 5 10) and Cy (120-200
mg/kg)1TBI (12-14Gy)1ATG(n5 8).GVHDpro-
phylaxis varied among the individual centers (Table 2).Female 38 58 ± 8 38 59 ± 8
P .049 .001
Sex match
Match 32 53 ± 8.5 32 26 ± 8
Mismatch 36 44 ± 9 36 46 ± 9
P .54 .36
Time from diagnosis to UCBT, months
>14 (median) 30 50 ± 9.5 30 43 ± 10
#14 30 37 ± 9 30 32 ± 9
P .52 .37
RBC transfusions
>20 35 54 ± 8 35 38 ± 9
#20 28 46 ± 11.5 28 41 ± 10
P .71 .83
Platelet transfusions
>20 42 52 ± 8 42 38 ± 8
#20 21 48 ± 11.5 21 43 ± 11
P .65 .87
CMV status
Positive 43 49 ± 8 43 42 ± 8
Negative 24 54 ± 10.5 24 38 ± 10
P .69 .52
ABO
Match or minor mismatch 41 51 ± 8 41 38 ± 8
Major mismatch 27 53 ± 10 27 36 ± 10
P 1.0 .64
HLA disparity
0-1 24 54 ± 10.5 24 44 ± 10
>1 41 59 ± 8.5 41 38 ± 10
P .6 .61
Transplant
Single 57 49 ± 6.5 57 37 ± 7
Double 14 50 ± 10.5 14 43 ± 14
P .84 .55
Conditioning regimen
RIC 46 48 ± 7.5 46 47 ± 8
Myeloablative 21 62 ± 11 21 24 ± 9
P .43 .11
TNCs  107/kg
Prefreezing > 3.9 43 58 ± 7.5 43 45 ± 8
Prefreezing # 3.9 21 33 ± 11 21 18 ± 9
P .03 .004
Infused > 2.6 43 56 ± 8 43 44 ± 8
Infused # 2.6 21 38 ± 11 21 20 ± 10
P .14 .04
CD34+ cells  105/kg
Prefreezing > 1.6 40 53 ± 8 40 46 ± 8
Prefreezing # 1.6 21 48 ± 11.5 21 24 ± 9
P .52 .05
Infused > 1.3 36 56 ± 8.5 36 45 ± 9
Infused # 1.3 18 39 ± 12 18 39 ± 12
P .5 .48
UD indicates unrelated donor; UCBTunrelated cord blood transplanta-
tion; SAA, severe aplastic anemia; OS, overall survival; RIC, reduced-
intensity conditioning; TNCs, total nucleated cells.Engraftment and Chimerism Studies
The CI (6 standard deviation) of neutrophil re-
covery (without evidence of rejection or autologous re-
covery) was 51%6 6%by day 60.Neutrophil recovery
occurred in 37 patients, at a median of 25 days (range,
6-91 days). Thirty-four patients showed no sign of
neutrophil recovery; 8 of these patients died early
(within 30 days post-UCBT), 4 had autologous recon-
stitution (still alive at the time of the analysis), 6 died in
aplasia, and 12 underwent a second transplantation
(4 with a single unit, 4 with a double UCBT and
4 with a transplant from a related mismatched donor),
of whom 2 are alive. Two out of 4 patients withmissing
data regarding the treatment of primary graft failure
were still alive at the time of the last analysis. In univar-
iate analysis, the following variables were associated
with a higher incidence of neutrophil recovery
(Table 3): recipient sex (58% for female vs 39% for
male; P 5 .05), prefreezing TNC dose .3.9  107/kg
(58% vs 33%; P5 .03), and infused TNC dose.3.4
107/kg (63% vs 39%; P 5 .03). In multivariate analy-
sis, the only factor associated with shorter time and
higher probability of engraftment was prefreezing
TNC dose .3.9  107/kg (HR, 1.5; 95% confidence
interval, 1-2.2; P 5 .05). The CI of neutrophil recov-
ery according to TNC dose before freezing is shown
in Figure 1.
The CI of platelet engraftment was 37% 6 7% by
day 180. Platelet recovery occurred in 29 patients
(46%) at a median of 45 days (range, 15-127 days). In
univariate analysis, the only factor associated with
higher incidence of platelet engraftment was prefreez-
ing TNC dose.3.9 107/kg; P5 .05). No factor was
associated with platelet engraftment in multivariate
analysis.
Chimerism was available for 32 of 37 patients who
engrafted (26 of 30 recipients of single-unit and 6 of 7
recipients of double-unit transplants). Among single-
unit recipients, 22 (85%) had complete chimerism
and 4 (15%) had mixed chimerism (2 became complete
chimeras during follow-up). In recipients of double-
unit UCBT, 5 (86%) had complete chimerism and 1
(14%) had mixed chimerism. In 5 evaluable patients,
engraftment was derived from one unit in 4 and from
both units in 1.Graft-versus-Host Disease
The CI of grade II-IV aGVHD was 20% 6 5%.
Fourteen of 57 single-unit UCBT recipients
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Figure 1. CI of neutrophil recovery according to TNC dose before
freezing.
Table 4. Causes of Death (n 5 42)
Cause n (%)
Infections 16 (38%)
Bacterial 5 (12%)
Viral 3 (7%)
Fungal 3 (7%)
Unknown 2 (5%)
EBV-associated LPD 3 (7%)
Rejection or graft failure 14 (32%)
Figure 2. Estimated 3-year OS according to TNC dose.
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2%) compared with 3 of 14 double-unit UCBT recipi-
ents (CI at 3 years, 17% 6 3%). Thirty-four patients
were assessable for cGVHD; the CI at 3 years was
18% 6 5%. Five patients (15%) developed limited
and 6 (18%) developed extensive cGVHD. Eight of
57 single UCBT recipients presented cGVHD (CI at
3 years, 17% 6 5%) compared with 3 of 14 double-
unit UCBT recipients (CI at 3 years, 25% 6 4%). Be-
cause of the low number of events, a prognostic factor
analysis for the incidence of aGVHD or cGVHD was
not performed.
OS
After a median follow-up time for survivors of 35
months (range, 8-83 months), the probability of OS
was 38% 6 6% at 3 years. The following factors were
associated with an improved OS rate (Table 3): recipi-
ent sex (59% for female vs 14% for male; P 5 .001),
prefreezing NC dose .3.9  107/kg (45% vs 18%;
P 5 .004), and infused NC dose .2.6  107/kg (44%
vs 20%; P5 .04). In multivariate analysis, the only fac-
tor associated with better OS was prefreezing NC dose
(.3.9  107/kg; HR, 0.39; 95% confidence interval,
0.2-0.78;P5 .007) (Figure 2).Of note, 16 of 21 patients
(76%) who received MA conditioning died compared
with 23 of 46 patients (50%) who received an RIC reg-
imen (P 5 .11). Forty-two patients died during the
study. As depicted in Table 4, infections (n 5 16;
38%) and graft failure (n 5 14; 32%) were the main
causes of death.GVHD 3 (7%)
Hemorrhage* 3 (7%)
Multiorgan failure 3 (7%)
Other† 3 (7%)
EBV indicates Epstein-Barr virus; LPD, lymphoproliferative disease;
GVHD, graft-versus-host disease.
*Includes lung (empyema; n 5 1); central nervous system, unknown
origin (n5 1); and gut (dysplasia; n 5 1).
†Includes interstitial pneumonitis (n5 1), veno-occlusive disease (n5 1),
and missing data (n 5 1).DISCUSSION
To the best of our knowledge, the current series is
the largest multicenter study reporting the outcomes
after UCBT for patients with SAA. We were able to
analyze 71 patients who underwent transplantation
over a 13-year period. The retrospective settings, theheterogeneity of conditioning regimens and supportive
care, aswell as changes inHSCTprocedures during the
study period, are definitive drawbacks to this type of
study. However, we confirm that the main problems
encounteredwithUCBT in SAA are the high incidence
of graft failure and infections. The 38%OS at 3 years is
quite similar to the 41%probability ofOS at 2 years re-
ported in a previous Japanese cooperative study that in-
cluded 31patients [21], and is clearly lower than the one
recently observed after transplants from an adult unre-
lated donor (UD) [11]. Themain finding of the present
study is the demonstration of the strong impact of
TNC dose (.3.9  107/kg) on outcome, both on en-
graftment and OS.
Graft rejection has been a major concern for
many years in SAA, and cell dose is a recognized key
factor for engraftment [28-30]. The low number of
hematopoietic progenitor cells and hematopoietic
stem cells in umbilical cord blood (UCB) translates
into an increased risk of graft failure and delayed
hematopoietic engraftment, which may be especially
Biol Blood Marrow Transplant 17:78-85, 2011 83Cord Blood Transplantation and Aplastic Anemiarelevant for patients with SAA. In the current study, the
rate of engraftment was poor (51% and 37% CI for
myelogenous and platelet engraftment, respectively)
but improved to 58% and 49%, respectively, for
patients receiving UCBT with prefreezing TNC dose
.3.9  107/kg. These data indicate that a patient
with a nonmalignant disease should receive a higher
cell dose than patients with malignant disease to
obtain engraftment. The current recommendations
are 4.9  107 TNC/kg at collection and 3.5  107
TNCs/kg at infusion [29]. Although this finding could
suggest a benefit from using two CB units, the small
number of patients who received two CB units in this
study precludes drawing meaningful conclusions
regarding the benefit of double-unit UCBT as an ap-
proach to increasing cell dose in this setting. The cur-
rent study also failed to show any relationship between
HLA match and outcomes as has been suggested re-
cently [31]. The huge impact of cell dose and small
sample size are possible explanations for this result.
Significantly improved transplantation outcomes
have been achieved recently by the use of less immuno-
genic bloodproducts, such as leukocyte-depleted eryth-
rocytes and platelets collected by cytapheresis [32,33].
Along with advances in supportive care and better
HLA matching, this could help explain the improved
outcomes of UD-HSCT in patients with SAA in the
last decade [7,8]. The long time from diagnosis to
transplantation (median, 14 months; range, 2-140
months) indicates that UCBT was the last option for
those patients. Furthermore, the majority of patients
were heavily transfused before transplantation. Thus,
increased risk of rejection because of the potential
alloimmunization induced by multiple transfusion
exposure and the long duration of disease before
transplantation could explain, at least in part, the high
rejection rate observed [34]. Patients’ pretransplanta-
tion anti-HLA antibodies seem to have an impact on
neutrophil and platelet engraftment after UCBT [35].
Unfortunately, we were not able to collect data on the
presence of HLA antibodies in this highly transfused
population and cannot speculate on their potential
role on engraftment. Progressive mixed chimerism is
known to lead to poor transplantation outcome in
HSCT for aplastic anemia [36]. The low proportion
of mixed chimerism in our study is congruent with the
low incidence of late rejection (n 5 2) and suggests
that once achieved, CB engraftment is durable.
The optimal conditioning regimen forUD-HSCT
remains uncertain [7,10,11,37-39]. In our cohort,
patients treated with a RIC regimen (mainly Flu-
based) showed a trend toward better OS compared
with patients who received a standard MA regimen.
Moreover, all patients who received TBI 12 Gy died
(n5 10; data not shown). Thus, if confirmed by others,
our findings suggest that an RIC regimen is preferred
over an MA regimen in patients with SAA undergoingUCBT to ensure engraftment and avoid regimen-
related morbidity and mortality. Among the few stud-
ies published with a reasonable number of patients
with SAA who underwent UCBT, the best results
were obtained from the combination of Flu 1 Cy 1
TBI with ATG [20] or without ATG [21]. The high
heterogeneity of conditioning regimens and the high
frequency of ATG use in the current study precluded
a meaningful analysis of the potential relationship on
outcome.
The global incidence of GVHD in our cohort was
low despite the degree of HLA mismatch (the majority
of our patients received a 4/6 graft). The high frequency
of ATG use might have contributed to this finding.
Nonetheless, the literature reports a relatively low inci-
dence of severeGVHDafter UCBT in SAA [20,21,40].
Thus, a single agent (ie, CsA or tacrolimus) could
provide effective GVHD prophylaxis after UCBT in
SAA, as has been suggested previously [21].
Infectious complications were a major concern in
our population and represented the primary cause of
mortality. Previous studies have reported a high rate of
severe or fatal infections in UCBT recipients [41,42],
especially in adult patients [43], concordant with the
delay in immune reconstitution [44]. This is not unex-
pected in our cohort considering themedian disease du-
ration (14 months) before UCBT.Once again, the high
rateofATGuse in the current studymight have contrib-
uted to the burden of infectious mortality. Moreover,
3 patients (7%) died from an Epstein-Barr virus
(EBV)-associated lymphoproliferative disorder (LPD).
Thus, weekly monitoring of EBV DNA levels in this
setting is essential [45]. Early use of anti-CD20 in
patients with increasing viral load also could be benefi-
cial [45-47].
In conclusion, this study demonstrates the pivotal
role of TNC dose (.3.9  107/kg TNCs/kg) on
both engraftment and OS using unrelated CB as the
stem cell source in patients with SAA. Graft failure
and infection remain major issues in this particularly
high-risk population. The result of well-designed pro-
spective trials, like one currently underway in France,
which incorporate the requirement of a large cell
dose and hopefully demonstrate better OS, are needed
before including UCBT in the treatment strategy for
SAA can be recommended.ACKNOWLEDGMENTS
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